ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples